Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsDenver-Health Step Therapy Coverage Update | OpenP…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentDenver-Health-Medical-PlanPolicy H5608_ST25_C

    Step Therapy Requirements — Part 1 (select drugs; Step 2 prior-therapy rules)

    Customize your policy alerts

    Sign up for Denver-Health-Medical-Plan Policy H5608_ST25_C alerts

    Get alerted when Policy H5608_ST25_C changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines step therapy (prior trial) requirements for specific drugs and formulations for Denver-Health-Medical-Plan Elevate Medicare Choice (HMO D-SNP) and Elevate Medicare Select (HMO). Affects providers submitting pharmacy claims or prior auth for listed products.

    Policy Summary
    PayerDenver-Health-Medical-Plan
    PolicyStep Therapy Requirements — Part 1 (select drugs; Step 2 prior-therapy rules)
    Policy CodePolicy H5608_ST25_C
    Change TypeNo material change
    Effective DateDec 1, 2025
    Next Review DateN/A
    Key ActionProvide prior pharmacy claim evidence per the listed lookback windows (typically 120 or 365 days) to meet Step 2 prior-therapy requirements.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    20+distinct product entries
    120 dayscommon look-back
    365 daysalternate look-back
    ~320supply line items
    part 8 of 9document segment

    Coverage Criteria — Step Therapy Details

    Febuxostat initial therapy

    Covered when ALL of the following are met for febuxostat (Step 2):

    Febuxostat Step 2 criteria: Prior claim for formulary version of allopurinol tablets within the past 120 days.120 days

    Applies to febuxostat 40 mg and 80 mg tablets

    Esomeprazole granules initial therapy

    Covered when ALL of the following are met for esomeprazole magnesium granules (Step 2):

    Esomeprazole granules Step 2 criteria: Prior claim for a generic federal-legend formulary oral PPI (lansoprazole capsules, esomeprazole magnesium capsules, rabeprazole, omeprazole, or pantoprazole) within the past 120 days.120 days

    Applies to esomeprazole magnesium DR granules 10 mg, 20 mg, 40 mg

    Policy Summary
    PayerDenver-Health-Medical-Plan
    PolicyStep Therapy Requirements — Part 1 (select drugs; Step 2 prior-therapy rules)
    Policy CodePolicy H5608_ST25_C
    Change TypeNo material change
    Effective DateDec 1, 2025
    Next Review DateN/A
    Key ActionProvide prior pharmacy claim evidence per the listed lookback windows (typically 120 or 365 days) to meet Step 2 prior-therapy requirements.
    SourceLink
    On This Page
    Coverage Criteria — Step Therapy DetailsCoding and Look-back WindowsWhat Providers Must Do / Denial RisksBackground and Policy ScopeDefinitions and Reference ListsInitial Therapy Examples and Required TrialsStep Therapy Assignments and Lookup

    Antipsychotic products criteria

    Covered when specified trials of formulary oral antipsychotics are documented:

    Oral antipsychotic trial (120-day look-back): Prior claim for one formulary oral antipsychotic (examples include risperidone, clozapine tablet, olanzapine, immediate‑release quetiapine fumarate, ziprasidone, aripiprazole [tablets/solution/film], asenapine, paliperidone, lurasidone) within the past 120 days.120 days

    Applies to certain disintegrating tablets and films

    Two oral antipsychotic trials (365-day look-back): Claims for two formulary oral generic antipsychotics (examples listed: lurasidone, risperidone, clozapine tab, olanzapine, IR quetiapine fumarate, ziprasidone, aripiprazole, asenapine, paliperidone) within the past 365 days.365 days

    Applies to some patches, dose packs, and other products requiring two-agent trial

    AUVELITY initial therapy

    Covered when ALL of the following are met for AUVELITY ER:

    AUVELITY Step 2 criteria: Prior claim for TRINTELLIX and one generic antidepressant (citalopram, escitalopram, fluoxetine, paroxetine, sertraline, desvenlafaxine, duloxetine, venlafaxine, mirtazapine, bupropion IR/SR/XL, or vilazodone) within the past 365 days.365 days

    Applies to AUVELITY 45 mg–105 mg ER tablet

    Dihydroergotamine initial therapy

    Covered when ALL of the following are met for dihydroergotamine nasal spray:

    Dihydroergotamine prior triptan requirement: Prior claim for two formulary generic triptans (e.g., sumatriptan and rizatriptan) within the past 365 days.365 days

    Applies to dihydroergotamine 0.5 mg/pump nasal spray

    ELEPSIA XR initial therapy

    Covered when ALL of the following are met for ELEPSIA XR:

    ELEPSIA XR prior-levetiracetam requirement: Trial of generic levetiracetam extended‑release tablets within the past 120 days.120 days

    Applies to ELEPSIA XR 1000 mg and 1500 mg ER tablets

    Eslicarbazepine (200 mg, 400 mg) initial Step requirement

    Coverage of eslicarbazepine 200 mg and 400 mg tablets (Step 2) when the following is met:

    Step 2 eslicarbazepine 200/400 mg: Prior claim for generic topiramate (tablets or capsules) within the past 120 days.120 days

    Applies to eslicarbazepine 200 mg and 400 mg tablets

    Eslicarbazepine (600 mg, 800 mg) Step requirement

    Coverage of eslicarbazepine 600 mg and 800 mg tablets (Step 2) when the following is met:

    Step 2 eslicarbazepine 600/800 mg: Prior claim for two generic anticonvulsant agents (from listed agents: carbamazepine, divalproex sodium, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine, topiramate, valproic acid, zonisamide, lacosamide) within the past 365 days.365 days

    Applies to eslicarbazepine 600 mg and 800 mg tablets

    Omega-3 acid ethyl esters Step requirement

    Coverage of omega-3 acid ethyl esters 1 g capsule (Step 2) when the following is met:

    Omega-3 Step 2: Prior claim for generic fenofibrate within the last 120 days.120 days

    Applies to omega‑3 acid ethyl esters 1 g capsule

    PCSK9 / LDL-lowering agents Step listing

    Coverage of listed PCSK9 inhibitor presentations and LDL‑lowering agents (Step 2) when the following is met:

    Repatha/Nexletol/Nexlizet Step 2: Products listed as Step 2 include NEXLETOL 180 mg, NEXLIZET 180/10 mg, REPATHA PUSHTRONEX 420 mg/3.5 mL wearable injector. Note: ST criteria pending CMS approval for REPATHA SURECLICK and REPATHA syringe presentations.

    Chunks 23–24

    FANAPT (iloperidone) Step requirement

    Coverage of FANAPT products (Step 2) when the following is met:

    FANAPT Step 2: Prior claim for two formulary oral generic antipsychotics (listed agents) within the past 365 days.365 days

    Applies to FANAPT tablets and titration packs

    Medical supplies and consumables Step 2 listing

    Coverage of listed medical supply items (pen needles, syringes, alcohol pads, gauze, etc.) as Step 2 items:

    Supply items Step 2 list: Enumerated list of Step 2 supply items (pen needles, insulin syringes, alcohol prep pads/swabs, gauze pads, bandages, safety syringes, etc.) as provided across chunks 27–37.

    No explicit prior-therapy criteria stated in these chunks for supplies; coverage contingent on the listed product being assigned Step 2

    Injectable insulin prior-claim criterion

    Criteria related to injectable insulin Part D payment

    Injectable insulin Part D payment: A prior claim for an injectable insulin within the past 120 days will qualify for Part D payment.120 days

    Used to assist Part D payment determination

    Trintellix + generic antidepressant prior-claim

    Criteria for Trintellix step requirement

    Trintellix step requirement: Prior claim for TRINTELLIX and one generic antidepressant (bupropion, citalopram, escitalopram, fluoxetine, mirtazapine, paroxetine, sertraline, venlafaxine, or vilazodone) within the past 365 days.365 days

    Required to meet step criteria for related products

    CAPLYTA step therapy

    Step therapy requirements for CAPLYTA products

    CAPLYTA step: Prior claim for two formulary oral generic antipsychotics (lurasidone, risperidone, olanzapine, immediate‑release quetiapine fumarate, ziprasidone, aripiprazole, asenapine) within the past 365 days.365 days

    Applies to CAPLYTA 10.5 mg, 21 mg, and 42 mg per listing

    Memantine prior-claim requirement

    Memantine extended‑release products

    Memantine XR step: Prior claim for formulary memantine immediate‑release within the past 120 days is required.120 days

    Applies to listed memantine ER sprinkle capsule strengths

    Methotrexate injector step/requirement

    Methotrexate injector coverage

    Methotrexate injector criteria: Trial of or documented contraindication to generic oral methotrexate tablet is required for coverage of RASUVO subcutaneous auto‑injector preparations.trial or documented contraindication

    Applies to listed methotrexate injector products

    Loteprednol prior-claim requirement

    Topical ophthalmic steroid (loteprednol) requirement

    Loteprednol prior-claim: Prior claim for federal‑legend levocetirizine, cromolyn sodium, or epinastine within the past 120 days is required.120 days

    Applies to ALREX / loteprednol etabonate 0.2%

    Perampanel/Fycompa step therapy

    Step 2 epilepsy products

    Perampanel step: Per listed Step 2 assignment for FYCOMPA/perampanel products; for higher‑strength tablets (10 mg, 12 mg) a prior claim for two generic anticonvulsant agents within the past 365 days is required.365 days for higher strengths

    Applies to perampanel oral suspension and tablets as listed

    Prior claim requirement (levocetirizine/cromolyn/epinastine)

    Coverage for the product(s) referenced under this Details entry is conditioned on ALL of the following:

    Prior claim for specific agents: Prior claim for federal‑legend levocetirizine, cromolyn sodium, or epinastine within the past 120 days.120 days

    Supports step‑therapy for the associated product grouping

    Perampanel tablet Step 2 prior-therapy

    Perampanel higher‑strength tablets Step 2 criteria:

    Prior trials of anticonvulsants: Prior claim for two generic anticonvulsant agents (carbamazepine, divalproex sodium, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine, topiramate, valproic acid, zonisamide, or lacosamide) within the past 365 days.365 days

    Applies to perampanel 10 mg and 12 mg tablets grouping

    Rufinamide prior-therapy

    Rufinamide product grouping criteria:

    Prior generic anticonvulsant: Prior claim for a generic anticonvulsant agent (carbamazepine, divalproex sodium, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine, topiramate, valproic acid, or zonisamide) within the past 120 days.120 days

    Applies to certain rufinamide strengths

    EMSAM prior-therapy

    EMSAM (selegiline patch) step criteria:

    Prior oral antidepressant: Prior claim of a formulary oral SSRI (citalopram, escitalopram, fluoxetine, paroxetine, or sertraline), an SNRI (desvenlafaxine, duloxetine, or venlafaxine), mirtazapine, or bupropion IR/SR/XL in the past 120 days.120 days

    Supports coverage of EMSAM patch formulations

    Antipsychotic prior-therapy

    Antipsychotic-related step requirements:

    Prior formulary oral antipsychotic: Claim for one formulary oral antipsychotic (lurasidone, risperidone, clozapine tablet, olanzapine, IR quetiapine fumarate, ziprasidone, aripiprazole, asenapine, paliperidone) within the past 120 days.120 days

    Applies to COBENFY/grouped entries and related products

    For certain oral alkylating agents and other immunomodulators, the policy requires documentation to support a Medicare Part B versus Part D payment determination. Specifically, a prior claim for a rheumatoid arthritis, psoriasis, or active polyarticular juvenile idiopathic arthritis drug within the past 120 days will qualify the drug for Part D payment; all other indications will be adjudicated through the formulary exception process prior to approval.

    REPATHA presentations are listed with an administrative status note: the ST Criteria: Pending CMS Approval designation applies to REPATHA SURECLICK 140 mg/mL pen and REPATHA syringe 140 mg/mL. This indicates a pending CMS decision rather than a defined prior‑therapy requirement at this time; providers should expect special administrative handling until CMS approval is resolved.

    Coverage for RASUVO subcutaneous auto‑injector products is conditioned on prior use of or a documented contraindication to generic oral methotrexate tablets. In other words, a trial of generic oral methotrexate or documentation of contraindication is required before RASUVO will be approved.

    SPRITAM (levetiracetam oral suspension/tablet for suspension) appears in the Step 2 product listings without any explicit exclusion language in this excerpt. The listing shows SPRITAM as Products Affected Step 2 but no separate exclusion clause is stated here.

    This portion of the document functions as an index only and does not list explicit coverage exclusions for the indexed items. Entries such as delayed‑release capsules, injectable supplies, and other products are shown for reference rather than presenting standalone coverage criteria or exclusions.

    Coding and Look-back Windows

    Indexed supply items (no billing codes listed)mixed
    No codes listed
    Look-back periods
    Standard look-back intervalsTwo look-back periods are used across step requirements: 120 days and 365 days, applied per product-specific Details lines.
    120-day examplesUsed for prior claims such as formulary allopurinol (febuxostat), generic topiramate, generic fenofibrate, memantine IR, injectable insulin qualification for Part D, and selected oral antipsychotic trials.
    365-day examplesUsed for multi-agent requirements such as two generic anticonvulsant trials and two formulary oral generic antipsychotic claims, and for TRINTELLIX + generic antidepressant prior-therapy for AUVELITY.
    Applied per Details lineEach Step 2 product's Details line specifies which look-back (120 or 365 days) is required; providers must follow the specified window for prior-claim evidence.
    Prior-claim lookback windows (120 days examples)
    120-day window (examples)Prior claim for generic topiramate within the past 120 days (used for eslicarbazepine 200/400 mg and other entries).
    Fenofibrate examplePrior claim for generic fenofibrate in the last 120 days is required for omega-3 acid ethyl esters Step 2 entry.
    Supply index timingSome supply and insulin-syringe entries reference product listings that may be identified using the same 120-day context for injectable insulin Part D qualification, where applicable.
    Prior-claim lookback windows (365 days examples)
    365-day window (examples)Requirement for prior claims for two generic anticonvulsant agents within the past 365 days (applies to eslicarbazepine 600/800 mg and higher-strength perampanel criteria).
    Two antipsychotic trialsClaims for two formulary oral generic antipsychotics within the past 365 days are required for certain antipsychotic Step 2 entries (per Details).
    TRINTELLIX + generic antidepressantPrior claim for TRINTELLIX plus one generic antidepressant within the past 365 days is required for AUVELITY Step 2 criteria (refer to Details).
    Prior-claim lookback (120 days)
    120-day prior-claim — febuxostatPrior claim for formulary version of allopurinol tablets within the past 120 days is required before febuxostat (40 mg/80 mg) is authorized as Step 2.
    120-day prior-claim — levetiracetam/ ELEPSIA XRTrial of generic levetiracetam ER tablets within the past 120 days is required before ELEPSIA XR extended-release products are approved.
    120-day prior-claim — rufinamidePrior claim for a generic anticonvulsant agent within the past 120 days is required for certain rufinamide strengths (per Details).
    Prior-claim lookback (365 days)
    365-day prior-claim — multi-agent anticonvulsant requirementPrior claim for two generic anticonvulsant agents within the past 365 days is required for eslicarbazepine 600 mg and 800 mg and for higher-strength perampanel tablet criteria.
    365-day prior-claim — antipsychotic multi-trialClaims for two formulary oral generic antipsychotics within the past 365 days are required for selected antipsychotic Step 2 products (see Details for agent list).
    365-day prior-claim — AUVELITYPrior claim for TRINTELLIX plus one generic antidepressant within 365 days is specified for AUVELITY Step 2 coverage criteria.
    Prior-claim lookback (mixed 120/365 days)
    Mixed windows applied by productSome product groups use a 120-day look-back for single-agent trials (e.g., generic topiramate, fenofibrate, memantine IR) while related higher-step or multi-agent rules require a 365-day window (e.g., two anticonvulsants; two antipsychotics). Follow the Details line per product.
    Examples — 120 then 365Eslicarbazepine 200/400 mg references a 120-day prior-claim for topiramate; eslicarbazepine 600/800 mg references two anticonvulsants within 365 days.
    Antidepressant vs anticonvulsant windowsTRINTELLIX + generic antidepressant uses 365 days, whereas many antidepressant or anticonvulsant single-agent trials use 120 days; apply per Details statement.

    What Providers Must Do / Denial Risks

    Step Therapy

    Esomeprazole granules prior‑claim requirement

    Esomeprazole granules (delayed‑release oral suspension granules) are subject to a Step 2 prior‑claim requirement. Providers must document a prior pharmacy claim within the past 120 days for a generic formulary oral proton‑pump inhibitor (examples listed in the policy: lansoprazole capsules, esomeprazole capsules, rabeprazole, omeprazole, or pantoprazole). Absence of such a prior claim may result in denial of the Step 2 product.

    • Products listed: esomeprazole magnesium DR 10 mg granules; esomeprazole magnesium DR 20 mg granules; esomeprazole magnesium DR 40 mg granules
    • Required lookback: 120 days
    • Acceptable prior agents: generic lansoprazole capsules, esomeprazole capsules, rabeprazole, omeprazole, pantoprazole
    Step Therapy

    Antipsychotic products prior‑claim requirement

    Many oral and transdermal antipsychotic products in the Step 2 group require evidence of prior use of formulary oral antipsychotics. Providers must show prior pharmacy claims within the specified lookback periods (typically 120 or 365 days depending on product) documenting trials of listed generic/formulary oral antipsychotics before Step 2 agents will be approved.

    • Examples of Step 2 antipsychotics: aripiprazole ODT, aripiprazole film, aripiprazole disintegrating tablets, cariprazine (Vraylar), Caplyta, Fanapt, Secuado (asenapine patch)
    • Common required prior agents: risperidone, clozapine tablet, olanzapine, immediate‑release quetiapine fumarate, ziprasidone, aripiprazole (tablets/film/solution), asenapine, paliperidone, lurasidone
    • Lookback windows: 120 days for many products; some require evidence of 2 different formulary oral generics within past 365 days
    Step Therapy

    Step 2 prior‑therapy verification

    For all Step 2 products, providers must verify prior‑therapy criteria exactly as stated for the specific product. This commonly requires one or more prior claims for listed generic or formulary agents within the stated lookback window (examples below). Failure to submit prior‑therapy documentation matching the policy criteria risks denial.

    • Confirm the exact prior agents and number required (e.g., one formulary oral antipsychotic vs. two distinct generic anticonvulsants)
    • Confirm the lookback period (commonly 120 days or 365 days as specified)
    • Attach prior pharmacy claim details to the authorization request (dates, NDC or drug name, and days supply)
    Note

    Product list only (supplies/index entries)

    This portion of the document also contains product and supplies index listings only. These index entries list product names, packaging, and page references — they are informational and do not by themselves state prior‑authorization or step‑therapy approval criteria.

    • Index entries include numerous pen needles, syringes, alcohol pads, gauze and other supplies
    • Index listings show page references for each product (useful for locating full policy text)
    Documentation Required

    Prior‑claim evidence required

    Several Step 2 entries require submission of prior‑claim evidence to meet criteria. Providers must include prior pharmacy claim records showing the agent(s) used, date(s) of dispensing within the policy lookback window, and sufficient detail to identify the formulary product (drug name and strength, NDC if available, and days supply).

    • Common lookback windows: 120 days or 365 days depending on product
    • Required details: drug name, strength, date of fill, and indication where relevant (e.g., insulin or rheumatologic agents for Part B vs Part D determination)
    • Examples: Trintellix + one generic antidepressant within past 365 days; generic topiramate within past 120 days; injectable insulin prior claim within past 120 days
    Prior Authorization

    Prior authorization conditioned on prior trials

    Prior authorization approvals for many Step 2 drugs are conditioned on prior trials of specified agents. Examples: trials of two distinct generic anticonvulsants within 365 days for certain anticonvulsant Step 2 products; trial of Trintellix plus one generic antidepressant in past 365 days for labeled antidepressant Step 2 products.

    • Anticonvulsant requirement examples: two generic agents from list (carbamazepine, divalproex, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine, topiramate, valproic acid, zonisamide, lacosamide) within past 365 days
    • Antidepressant example: prior claim for Trintellix and one generic antidepressant within 365 days
    Note

    Prior authorization (none stated)

    Some index portions and product listings do not specify a prior authorization requirement in the excerpted text. For those entries, no specific prior‑auth criteria are stated on the index page; providers should consult the full policy text at the referenced page for any action requirements.

    • Index-only entries (supplies and some drug names) show no explicit prior authorization criteria in this section
    • If an authorization is needed, the detailed criteria will appear in the product detail pages referenced by the index
    Note

    No explicit authorization or denial criteria in index entries

    Several entries in the provided pages contain no explicit authorization or denial criteria (index or supply listings). These are informational; providers should not infer step‑therapy rules from index lines alone and must review the detailed product sections for coverage rules.

    • Examples: supply index lines and simple product name listings without adjacent 'Details' criteria
    • These entries are not actionable for prior authorization without the product detail page
    Denial Risk

    Lack of a prior claim for Trintellix plus a generic antidepressant may cause denial

    For Trintellix‑related Step 2 criteria, providers must document a prior claim for Trintellix plus one generic antidepressant within the past 365 days. Lack of documented prior use of Trintellix plus a qualifying generic antidepressant will not meet the Step 2 requirement and may result in denial.

    • Required prior agents: Trintellix plus one generic antidepressant (examples: citalopram, escitalopram, fluoxetine, paroxetine, sertraline, desvenlafaxine, duloxetine, venlafaxine, mirtazapine, bupropion IR/SR/XL, vilazodone)
    • Lookback window: 365 days
    Documentation Required

    Prior claim required (120 days) for certain ocular/allergy agents

    Certain ocular and allergy agents (e.g., ALREX, loteprednol etabonate) require documentation of a prior pharmacy claim for specified agents (levocetirizine, cromolyn sodium, or epinastine) within the past 120 days. Providers should include these prior claims when requesting Step 2 products to avoid denial.

    • Examples: ALREX 0.2% eye drops; loteprednol etabonate 0.2% eye drops
    • Required prior agents: levocetirizine, cromolyn sodium, or epinastine
    • Lookback: 120 days
    Step Therapy

    Prior trial of two generic anticonvulsants (365 days)

    Some anticonvulsant Step 2 approvals require documented trials of two different generic anticonvulsants within the past 365 days (example agents listed in policy). Providers must present claims for two distinct qualifying agents with dates within the 365‑day lookback to satisfy these criteria.

    • Qualifying generic anticonvulsants include: carbamazepine, divalproex sodium, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine, topiramate, valproic acid, zonisamide, lacosamide
    • Lookback window: 365 days
    • Applies to products like eslicarbazepine and perampanel/Fycompa Step 2 listings
    Note

    No denial criteria are present in these index listings

    Multiple index pages contain no denial criteria or authorization triggers visible in the index excerpts; these are purely navigational product lists. Providers should reference the corresponding detailed product pages for any required documentation or prior authorization steps.

    • Index lists of pen needles, syringes, supplies and many product names show no authorization language in the index
    • Use page references in the index to find the detailed criteria
    Billing Rule

    Part B vs Part D payment determination documentation

    The document includes notes to assist with Part B vs Part D payment determinations. For certain agents (e.g., cyclophosphamide, methotrexate), providers should include documentation of the indication (rheumatoid arthritis, psoriasis, active polyarticular juvenile idiopathic arthritis) and prior pharmacy claims within the stated lookback to qualify for Part D payment. Otherwise a Part B vs D determination will be made via the formulary exception process.

    • Example: Cyclophosphamide entries include a Part B vs D payment determination note
    • Required supporting info: prior claim for a rheumatologic agent within past 120 days; indication documentation may be needed
    Documentation Required

    Documentation must show prior pharmacy claims meeting lookback criteria

    Documentation submitted for prior‑therapy verification must show prior pharmacy claims within the exact lookback periods specified in the policy. Include drug name, dispensing date, NDC if available, days supply, and, when relevant, the clinical indication to support Part B vs Part D determinations.

    • Required elements: drug name, strength, date of fill, NDC (if available), days supply
    • Match the lookback window specified (e.g., 120 days or 365 days)
    • For Part B vs D issues, include diagnosis/indication documentation
    Note

    The document provides product names and page references (index)

    Several sections explicitly state that the page is an index of supplies or injectables and that product names and page references are provided for navigation. These listings are operational aids; they do not replace the detailed product criteria in the policy.

    • Index lists injectable product names and page numbers (e.g., Rasuvo injectors, Repatha injectors)
    • Index also lists many supply items (pen needles, syringes, alcohol pads)
    Note

    This section is an index of supply and drug names (no actionable criteria)

    This section contains many index entries only (supply and drug name indexes). There are no step‑therapy actions or requirements stated on those index lines — providers must consult the referenced product detail pages for any coverage rules or prior authorization instructions.

    • Index entries are for navigation; they do not show 'Details' criteria on the index page
    • Locate the detailed criteria by page reference when an authorization is required
    Step Therapy

    Cyclophosphamide Step 2 and Part B/D note

    Cyclophosphamide Step 2 entries include both Step 2 placement and a Part B vs D note — providers should submit prior therapy evidence for indicated rheumatologic agents within the past 120 days to support Part D payment; otherwise a Part B vs D determination will be performed.

    • Cyclophosphamide products listed as Step 2: 25 mg and 50 mg tablets/capsules
    • Part B vs D qualifier: prior claim for rheumatoid arthritis, psoriasis, or active polyarticular juvenile idiopathic arthritis drug within past 120 days will qualify for Part D payment

    Background and Policy Scope

    Background: This section defines the policy’s step therapy (Step 2) approach. Step assignments require documentation of prior pharmacy claims or trials of specified formulary or generic alternatives within defined look‑back windows (commonly 120 days or 365 days, depending on the product). Certain entries include administrative notes affecting payment pathway or CMS approval status (for example, Part B vs D determinations for immunomodulators and a pending CMS approval status for specific REPATHA presentations). Indexed pages list supply and injectable product names but do not, by themselves, define authorization criteria.

    Definitions and Reference Lists

    Part B vs Part D payment determination
    PurposeProcess to determine whether a drug is payable under Medicare Part B or Part D; a prior claim for a rheumatoid arthritis, psoriasis, or active polyarticular juvenile idiopathic arthritis drug within the past 120 days will qualify for Part D payment.
    Other indicationsAll other indications will require a Part B vs. D payment determination through the formulary exception process prior to approval.
    Use in adjudicationProviders may need to submit indication documentation or prior pharmacy claims to support Part B vs Part D determinations per the Details line.
    PRIOR CLAIM definition
    DefinitionA PRIOR CLAIM is a previously adjudicated pharmacy claim for the specified agent(s) within the look-back period referenced in the product's Details criteria.
    Evidence acceptedPrior pharmacy adjudication (claim) for the named formulary/generic agent(s) within the stated look-back window (e.g., 120 or 365 days).
    Provider actionSubmit prior pharmacy claim history showing the required agent(s) and dates to meet Step 2 Details criteria.
    FORMULARY ORAL GENERIC ANTIPSYCHOTICS definition
    ScopeFormulary oral generic antipsychotics refers to the listed agents used as required prior therapy in Details lines (examples include lurasidone, risperidone, clozapine tablet, olanzapine, immediate-release quetiapine fumarate, ziprasidone, aripiprazole, asenapine, paliperidone).
    Single-agent vs multi-agent useSome Step 2 entries require a single prior claim within 120 days for one formulary oral antipsychotic; other products require claims for two formulary oral antipsychotics within 365 days.
    Reference to Details linesProviders must check the product-specific Details line for the exact agent list and look-back window when documenting prior antipsychotic trials.
    Product line items (supply descriptors)
    ContentsProduct line items enumerate insulin syringes, pen needles, alcohol swabs, gauze, and related consumables with gauge and length specifications (examples: 29–33 gauge; lengths 1/4" to 1/2").
    Brand examplesEntries include brand-style names such as EASY COMFORT, EASY GLIDE, EASY TOUCH and many pen-needle and syringe variations listed in the index pages.
    Claim identificationSupplies are listed individually across the index and should be identified by the exact product line/item when submitting claims or authorizations.
    Prior claim (short form)
    Short form definitionPrior claim: previously adjudicated pharmacy claim for the named agent(s) within the look-back period required by the Details criteria.
    UseUsed throughout the policy as the evidentiary trigger to satisfy Step 2 prior-therapy requirements.
    Provider requirementSubmit prior claims showing the agent name(s) and dates within the stated window to support coverage decisions.
    Generic anticonvulsant agents list
    Included agents (selected)Carbamazepine, divalproex sodium, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine, topiramate, valproic acid, zonisamide, lacosamide are listed as generic anticonvulsant agents used to satisfy multi-agent prior-claim requirements.
    Use caseTwo-agent claims from this list within 365 days are required for certain Step 2 entries (e.g., eslicarbazepine 600/800 mg, perampanel higher-strength tablets).
    Single-agent useA single prior claim for one of these agents within 120 days may satisfy other product-specific Details (see rufinamide example).
    Formulary oral antidepressants list
    Included antidepressants (examples)Formulary oral antidepressants listed include SSRIs (citalopram, escitalopram, fluoxetine, paroxetine, sertraline), SNRIs (desvenlafaxine, duloxetine, venlafaxine), mirtazapine, and bupropion IR/SR/XL; these are acceptable prior therapies per Details lines.
    TRINTELLIX pairingPrior claim for TRINTELLIX plus one generic antidepressant from this list within the past 365 days is required for AUVELITY Step 2 criteria.
    EMSAM contextA prior claim for a formulary oral SSRI/SNRI/mirtazapine or bupropion in the past 120 days is referenced for EMSAM patch Step entries (see Details).
    Insulin syringes / pen needles (definition/list reference)
    DefinitionInsulin syringes and pen needles encompass listed brand names and specific gauge/length variants used for subcutaneous insulin administration (index entries list numerous sizes and brands).
    Typical specificationsDocumented sizes include 0.3 mL, 0.5 mL, 1 mL syringes and pen needles in 29–33 gauge with lengths such as 1/4", 3/16", 5/32", 5/16", and 1/2".
    Index useProviders should reference the exact indexed product name/size when submitting supply claims or IDs for reimbursement or prior authorization.
    Pen needle / Insulin syringe (definition/list reference)
    Pen needle / syringe descriptorsIndex entries specify pen needle and insulin syringe options by gauge and length (examples: pen needle 31 gauge x 3/16"; syringe 1 mL 31 gauge x 15/64").
    Multiple brandsNumerous branded pen-needle and syringe product lines (e.g., COMFORT EZ, EASY COMFORT, PURE COMFORT, EASY TOUCH) appear in the index across the supply pages.
    Claim identification guidanceWhen charging or authorizing supplies, use the exact product line/item from the index to match coverage listings and avoid denials.
    (No entry)This definition placeholder has no content in the source document.
    UsageNo term or definition provided for this placeholder in the indexed fragments.
    ActionNo provider-facing definition to apply; consult the product-specific Details lines as needed.

    Initial Therapy Examples and Required Trials

    Initial therapy examples

    Initial therapy step rules included in this part:

    Febuxostat Step 2: Prior claim for formulary allopurinol tablets within 120 days required.120 days

    Example initial therapy rule: febuxostat 40 mg and 80 mg

    Initial Step 2 therapy requirements

    Initial Step 2 verification: Verify prior‑therapy claims per Details lines (examples: prior claim for generic topiramate within 120 days for certain eslicarbazepine strengths; two generic anticonvulsants within 365 days for higher eslicarbazepine strengths; prior claim for generic fenofibrate within 120 days for omega‑3; verification of two oral antipsychotic claims within 365 days for listed antipsychotics).

    See Details chunks 18–26 for specific agent lists and lookback windows

    Step Therapy Assignments and Lookup

    Product (Step Level)Prior-therapy / Look-back RequirementNotes
    febuxostat 40 mg tablet
    Prior claim for formulary version of allopurinol tablets within the past 120 days
    Designated Step 2; applies to febuxostat 40 mg and 80 mg listings
    Example Prior-claim ScenarioRequired prior pharmacy claim(s)Look-back window (days)
    Eslicarbazepine 200 mg / 400 mg (example)
    Prior claim for generic topiramate (tablets or capsules)
    120
    Eslicarbazepine 600 mg / 800 mg (example)
    Prior claims for two generic anticonvulsant agents (listed agents)
    365
    Omega-3 acid ethyl esters 1 g capsule (example)
    Prior claim for generic fenofibrate
    120
    Product (Step Level)Prior-therapy RequirementLook-back (days)
    CAPLYTA 10.5 mg capsule
    Claim for 2 formulary oral generic antipsychotics (lurasidone, risperidone, olanzapine, immediate‑release quetiapine fumarate, ziprasidone, aripiprazole, asenapine)
    365
    CAPLYTA 21 mg capsule
    Claim for 2 formulary oral generic antipsychotics (same agent list)
    365
    CAPLYTA 42 mg capsule
    Claim for 2 formulary oral generic antipsychotics (same agent list)
    365
    Product (Step Level)Required prior claimLook-back (days)
    memantine 7 mg / 14 mg / 21 mg / 28 mg capsule (extended‑release sprinkle strengths)
    Prior claim for formulary version of memantine immediate‑release
    120
    Product (Step Level)Prior-therapy requirementLook-back (days)
    ALREX / loteprednol etabonate 0.2% (eye drops)
    Prior claim for federal legend levocetirizine, cromolyn sodium, or epinastine
    120
    Product (Step Level)Prior-therapy requirementLook-back (days)
    FYCOMPA 0.5 mg/mL oral suspension
    Per listing: assigned Step 2 (prior‑therapy details for higher strengths noted separately)
    See perampanel table
    Perampanel 10 mg tablet / 12 mg tablet
    Prior claim for 2 generic anticonvulsant agents (listed agents) for higher‑strength tablets
    365
    Product groupingRequired prior pharmacy claim(s)Look-back (days)
    Perampanel (10 mg, 12 mg tablets) and FYCOMPA suspension
    Prior claim for 2 generic anticonvulsant agents (carbamazepine, divalproex sodium, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine, topiramate, valproic acid, zonisamide, lacosamide)
    365
    Rufinamide (200 mg, 40 mg/mL suspension; 400 mg tablet)
    Prior claim for a generic anticonvulsant agent (listed agents)
    120
    Products referencing topiramate criterion (e.g., eslicarbazepine 200/400 mg)
    Prior claim for generic topiramate (tablets or capsules)
    120
    Index segmentStep therapy rules presentNotes
    Index entries (supplies and miscellaneous) — page index excerpt
    No step therapy rules present in this index segment
    Content is an item index (e.g., gauze, syringes); use index references for locating product listings
    Index fragmentStep therapy requirementsNotes
    Index fragment showing dose‑pack capsule entries (VRAYLAR dose pack example)
    No step therapy requirements specified in this index fragment
    Fragment is an index listing only; no coverage criteria included in these lines